155 related articles for article (PubMed ID: 38481495)
1. A Prospective Study on Complement Activation Distinguishes Focal Segmental Glomerulosclerosis from Minimal Change Disease.
Cambier A; Patey N; Royal V; Gougeon F; Genest DS; Brachemi S; Bollée G; Merlen C; Bonnefoy A; Lapeyraque AL; Troyanov S
Kidney Int Rep; 2024 Mar; 9(3):661-670. PubMed ID: 38481495
[TBL] [Abstract][Full Text] [Related]
2. Urinary low-molecular-weight protein excretion in pediatric idiopathic nephrotic syndrome.
Chehade H; Parvex P; Poncet A; Werner D; Mosig D; Cachat F; Girardin E
Pediatr Nephrol; 2013 Dec; 28(12):2299-306. PubMed ID: 23949592
[TBL] [Abstract][Full Text] [Related]
3. Potential Urine Proteomic Biomarkers for Focal Segmental Glomerulosclerosis and Minimal Change Disease.
Chebotareva NV; Vinogradov A; Brzhozovskiy AG; Kashirina DN; Indeykina MI; Bugrova AE; Lebedeva M; Moiseev S; Nikolaev EN; Kononikhin AS
Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293475
[TBL] [Abstract][Full Text] [Related]
4. Immunoglobulin G/albumin staining in tubular protein reabsorption droplets in minimal change disease and focal segmental glomerulosclerosis.
Bu L; Mirocha J; Haas M
Nephrol Dial Transplant; 2021 May; 36(6):1016-1022. PubMed ID: 32191308
[TBL] [Abstract][Full Text] [Related]
5. CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance.
Cara-Fuentes G; Wei C; Segarra A; Ishimoto T; Rivard C; Johnson RJ; Reiser J; Garin EH
Pediatr Nephrol; 2014 Aug; 29(8):1363-71. PubMed ID: 24263531
[TBL] [Abstract][Full Text] [Related]
6. Urinary soluble HLA class I antigen in patients with minimal change disease: a predictor of steroid response.
Park CW; Song HC; Shin YS; Ahn SJ; Kim YS; Kim SY; Choi EJ; Chang YS; Bang BK
Nephron; 1998; 79(1):44-9. PubMed ID: 9609461
[TBL] [Abstract][Full Text] [Related]
7. Urinary fibrinogen and renal tubulointerstitial fibrinogen deposition: Discriminating between primary FSGS and minimal change disease.
Wang Y; Zheng C; Xu F; Liu Z
Biochem Biophys Res Commun; 2016 Sep; 478(3):1147-52. PubMed ID: 27539323
[TBL] [Abstract][Full Text] [Related]
8. Circulating and urinary microRNA profile in focal segmental glomerulosclerosis: a pilot study.
Ramezani A; Devaney JM; Cohen S; Wing MR; Scott R; Knoblach S; Singhal R; Howard L; Kopp JB; Raj DS
Eur J Clin Invest; 2015 Apr; 45(4):394-404. PubMed ID: 25682967
[TBL] [Abstract][Full Text] [Related]
9. Urinary N-acetyl-beta-glucosaminidase excretion is a marker of tubular cell dysfunction and a predictor of outcome in primary glomerulonephritis.
Bazzi C; Petrini C; Rizza V; Arrigo G; Napodano P; Paparella M; D'Amico G
Nephrol Dial Transplant; 2002 Nov; 17(11):1890-6. PubMed ID: 12401843
[TBL] [Abstract][Full Text] [Related]
10. Analysis of glomerular deposition of IgM and C3 in patients with podocytopathies.
Aparecida Ferreira V; Aparecida da Silva C; Rodrigues do Carmo Neto J; Rocha LP; Monteiro Dos Santos Martins AL; Antônia Dos Reis M; Machado JR
Ann Diagn Pathol; 2024 Jun; 70():152292. PubMed ID: 38484478
[TBL] [Abstract][Full Text] [Related]
11. In situ evaluation of podocytes in patients with focal segmental glomerulosclerosis and minimal change disease.
da Silva CA; Monteiro MLGDR; Araújo LS; Urzedo MG; Rocha LB; Dos Reis MA; Machado JR
PLoS One; 2020; 15(11):e0241745. PubMed ID: 33147279
[TBL] [Abstract][Full Text] [Related]
12. Cytotoxic T- Lymphocyte Antigen-4 (CTLA4) Gene Expression and Urinary CTLA4 Levels in Idiopathic Nephrotic Syndrome.
Mishra OP; Chhabra P; Narayan G; Srivastava P; Prasad R; Singh A; Abhinay A; Batra VV
Indian J Pediatr; 2019 Jan; 86(1):26-31. PubMed ID: 29968132
[TBL] [Abstract][Full Text] [Related]
13. Comparative differential proteomic analysis of minimal change disease and focal segmental glomerulosclerosis.
Pérez V; López D; Boixadera E; Ibernón M; Espinal A; Bonet J; Romero R
BMC Nephrol; 2017 Feb; 18(1):49. PubMed ID: 28158993
[TBL] [Abstract][Full Text] [Related]
14. Glomerular tip lesion: a distinct entity within the minimal change disease/focal segmental glomerulosclerosis spectrum.
Stokes MB; Markowitz GS; Lin J; Valeri AM; D'Agati VD
Kidney Int; 2004 May; 65(5):1690-702. PubMed ID: 15086908
[TBL] [Abstract][Full Text] [Related]
15. Quantification of Glomerular Structural Lesions: Associations With Clinical Outcomes and Transcriptomic Profiles in Nephrotic Syndrome.
Hodgin JB; Mariani LH; Zee J; Liu Q; Smith AR; Eddy S; Hartman J; Hamidi H; Gaut JP; Palmer MB; Nast CC; Chang A; Hewitt S; Gillespie BW; Kretzler M; Holzman LB; Barisoni L;
Am J Kidney Dis; 2022 Jun; 79(6):807-819.e1. PubMed ID: 34864148
[TBL] [Abstract][Full Text] [Related]
16. Reduced podocin expression in minimal change disease and focal segmental glomerulosclerosis is related to the level of proteinuria.
Agrawal V; Prasad N; Jain M; Pandey R
Clin Exp Nephrol; 2013 Dec; 17(6):811-8. PubMed ID: 23377573
[TBL] [Abstract][Full Text] [Related]
17. Case series: CTLA4-IgG1 therapy in minimal change disease and focal segmental glomerulosclerosis.
Garin EH; Reiser J; Cara-Fuentes G; Wei C; Matar D; Wang H; Alachkar N; Johnson RJ
Pediatr Nephrol; 2015 Mar; 30(3):469-77. PubMed ID: 25239302
[TBL] [Abstract][Full Text] [Related]
18. Urinary peptide profiling to differentiate between minimal change disease and focal segmental glomerulosclerosis.
Pérez V; Ibernón M; López D; Pastor MC; Navarro M; Navarro-Muñoz M; Bonet J; Romero R
PLoS One; 2014; 9(1):e87731. PubMed ID: 24498182
[TBL] [Abstract][Full Text] [Related]
19. [The clinic significance of urinary podocytes in patients with focal segmental glomerulosclerosis].
Li YH; Huang HC; Liu G; Zhang YK
Beijing Da Xue Xue Bao Yi Xue Ban; 2004 Apr; 36(2):135-8. PubMed ID: 15100729
[TBL] [Abstract][Full Text] [Related]
20. Urinary CD80 is elevated in minimal change disease but not in focal segmental glomerulosclerosis.
Garin EH; Mu W; Arthur JM; Rivard CJ; Araya CE; Shimada M; Johnson RJ
Kidney Int; 2010 Aug; 78(3):296-302. PubMed ID: 20485332
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
